[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doctor-en-liu-guolong":3,"doctor-lang-ok-en-liu-guolong":91},{"id":4,"slug":5,"name":6,"credentials":7,"titles":8,"specialtyName":12,"hospitalName":13,"spokenLanguages":14,"avatarSource":17,"detailHeroSource":18,"clinicalTags":19,"clinicalFocus":34,"expertise":35,"currentPosition":36,"department":12,"academicRole":37,"academicRoleDesc":38,"credentialsList":39,"educations":44,"publications":60,"locations":83,"seoTitle":89,"seoDescription":90},6,"liu-guolong","Liu Guolong","PhD in Oncology",[9,10,11],"Chief Physician","Professor","Postdoctoral Co-Supervisor","Medical Oncology","Shenzhen Qianhai Taikang Hospital",[15,16],"English","Mandarin","https:\u002F\u002Fatt.lumalinkglobal.com\u002Fcarepath\u002Fdoctor\u002F42c0c557-e469-4c17-864c-ad2a9e29f608.png","https:\u002F\u002Fatt.lumalinkglobal.com\u002Fcarepath\u002Fdoctor\u002F5f1bd121-9255-499e-8497-fa747393e11a.png",{"conditions":20,"procedures":27},[21,22,23,24,25,26],"Nasopharyngeal Carcinoma","Lung Cancer","Liver Cancer","Colorectal Cancer","Esophageal Cancer","Solid Tumors",[28,29,30,31,32,33],"Chemotherapy","Chemoradiotherapy","Targeted Therapy","Immunotherapy","Multimodal Cancer Treatment","Sphincter-Preserving Treatment for Colorectal Cancer",[21,28,22],"\u003Cp>Professor Guolong Liu is a medical oncologist with more than 35 years of experience in the multidisciplinary treatment of solid tumors. His clinical strengths include combined chemoradiotherapy for nasopharyngeal carcinoma, early detection and systemic treatment of lung and liver cancers, and sphincter-preserving treatment strategies for colorectal cancer. He integrates chemotherapy, targeted therapy, immunotherapy, radiotherapy and local treatment according to tumor type and disease stage. This broad multimodal perspective is particularly valuable for patients who require individualized sequencing of several treatment approaches.\u003C\u002Fp>","Director, Department of Medical Oncology","Doctoral and Master's Supervisor","Multimodal treatment of solid tumors, including chemoradiotherapy, targeted therapy and immunotherapy",[40,41,42,43],"Chair, Radiation Therapy Society, Guangzhou Medical Association","Vice President, Guangzhou Anti-Cancer Association","Chair, Specialty Committee of Hyperthermia and Ablation Therapy","Standing Committee Member, Oncology Society of Guangdong Medical Association",[45,50,55],{"year":46,"title":47,"institution":48,"description":49},1994,"Doctoral degree in Oncology","First Military Medical University","Earned a doctoral degree in oncology from First Military Medical University in 1994.",{"year":51,"title":52,"institution":53,"description":54},1990,"Master's degree in Oncology","Shanghai Second Medical University","Earned a master's degree in oncology from Shanghai Second Medical University between 1987 and 1990.",{"year":56,"title":57,"institution":58,"description":59},1987,"Bachelor's degree in Clinical Medicine","Suzhou Medical College","Earned a bachelor's degree in clinical medicine from Suzhou Medical College between 1982 and 1987.",[61,65,69,73,76,79],{"title":62,"journal":63,"year":64},"NRI and SIRI are the optimal combinations for prognostic risk stratification in patients with non-small cell lung cancer after EGFR-TKI therapy","Clinical & Translational Oncology",2025,{"title":66,"journal":67,"year":68},"Circulating tumor cells as a new predictive and prognostic factor in patients with small cell lung cancer","Journal of Cancer",2020,{"title":70,"journal":71,"year":72},"MicroRNA-148b regulates tumor growth of non-small cell lung cancer through targeting MAPK\u002FJNK pathway","BMC Cancer",2019,{"title":74,"journal":67,"year":75},"The Impact of Clinical Stage on Radiation Doses to Organs at Risk Following Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma",2016,{"title":77,"journal":78,"year":75},"IL-17A promotes migration and tumor killing capability of B cells in esophageal squamous cell carcinoma","Oncotarget",{"title":80,"journal":81,"year":82},"miR-148b functions as a tumor suppressor in non-small cell lung cancer by targeting carcinoembryonic antigen","International Journal of Clinical and Experimental Medicine",2014,[84],{"institution":13,"address":85,"latitude":86,"longitude":87,"isPrimary":88},"No. 3099 Menghai Avenue, Nanshan District, Shenzhen, Guangdong 518052, China","22.516998","113.896874",true,"Liu Guolong - Oncology Expert with 35 Years Experience","Professor Liu Guolong is a renowned medical oncologist specializing in cancer treatment and research. Learn about his expertise and approach.",{"en":88}]